期刊文献+

重症监护病房患者应用哌拉西林/舒巴坦的合理性分析 被引量:1

Rationality in the Utilization of Piperacillin/Sulbactam for ICU Patients
下载PDF
导出
摘要 目的:评价遂宁市中心医院重症患者哌拉西林/舒巴坦的应用情况,为合理用药提供依据。方法:采用回顾性分析方法,调查我院重症监护病房2010年1月—2011年3月使用哌拉西林/舒巴坦150例,统计、分析基础疾病、细菌学培养及药敏试验结果,评价用药合理性。结果:在150例患者中,治疗用药112例,有效97例,无效7例,死亡8例,总有效率为86.6%;预防用药38例,有效35例,无效3例,总有效率为92.1%。结论:哌拉西林/舒巴坦对重症患者治疗有效,为保持有效性应促进其合理应用。 OBJECTIVE: To evaluate the utilization of piperacillin/sulbactam in Sichuan Suining Municipal Central Hospital in ICU patients so as to provide references for clinical rational use of piperacillin/sulbactam. METHODS: A retrospective study was performed in 150 ICU patients treated with piperacillin/sulbactam from Jan. 2010 to Mar. 201 I. The data regarding the patients' basic diseases, bacterial culture and drug sensitivity test were analyzed statistically and the rationality of drug use was evaluated. RESULTS: Of the 150 patients, 112 received piperacillin/sulbactam for treatment purpose, of whom,97 had response ,7 did not have a response, and 8 died, with a total effective rate of 86.6% ; 38 received drugs for prophylactic purpose ,of whom,35 had response and 3 did not have response to treatment, with total effective rate of 92. 1%. CONCLUSION: Piperacillin/sulbactam therapy is effective for ICU patients ,however,the efficacy of which is dependent on its rational use.
作者 张兴 米佳丽
出处 《中国医院用药评价与分析》 2012年第1期77-79,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 哌拉西林/舒巴坦 重症患者 分析 合理用药 Piperacillin/sulbactam ICU patients Analysis Rational drug use
  • 相关文献

参考文献6

二级参考文献21

  • 1刘振桐,王承敏.阿齐霉素与头孢他啶联用对铜绿假单胞菌生物被膜作用的研究[J].中国呼吸与危重监护杂志,2004,3(5):318-319. 被引量:9
  • 2殷秀贞,时萍,彭红艳,姜思通.148例铜绿假单胞菌感染病例的耐药监测和用药分析[J].中国药房,2005,16(18):1406-1408. 被引量:10
  • 3刘建华,刘勇.β-内酰胺类和大环内酯类药物联合应用治疗社区获得性肺炎[J].中国抗生素杂志,2007,32(1):1-5. 被引量:35
  • 4Yoshimura H, To H, Narita C, et al. Antimicrobial susceptibility patterns of Pseudomonas aeruginosa isolated from 2006 to 2008 in Fukuoka University Hospital[J]. Jpn JAntibiot, 2009,62(6) : 502.
  • 5Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial[J]. JAMA, 2010, 303 (17) : 1 707.
  • 6YousefAA, Jaffe A. The role of azithromycin in patients with cystic fibrosis[J]. Paediatr Respir Rev, 2010, 11 (2) : 108.
  • 7Lin E, Stank RJ, Mufson MA. Lack of synergy of Erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro[J]. Antimicrob Agents Chemother, 2003,47 (3) : 1 151.
  • 8Johansen HK, Jensen TG, Dessau RB, et al. Antagonism between penicillin and erythromycln against Strepto- coccus pneumoniae in vitro and in vivo[J]. J Antimicrob Chemother, 2000,46 (6): 973.
  • 9Skarphedinn H, Thorarinn G, Magnus G, et al. Azithromycin maintains airway epithelial integrity during pseudo- monas aeruginosa infection[J]. Am J Respir Cell Mol Biol, 2010,42(1):62.
  • 10金大鹏.2007年北京地区医疗机构抗茵药物临床应用指南[M].上海:第二军医大学出版社,2007.

共引文献109

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部